CygnuSupreme
2021-11-24
Please like
iX Biopharma hands Seelos exclusive rights for lead drug Wafermine
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
4
7
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":874308923,"tweetId":"874308923","gmtCreate":1637726133198,"gmtModify":1637726133361,"author":{"id":4087222401581540,"authorId":4087222401581540,"authorIdStr":"4087222401581540","name":"CygnuSupreme","avatar":"https://static.tigerbbs.com/62707642aa348511f75a894c9de636e6","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":21,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Please like</p></body></html>","htmlText":"<html><head></head><body><p>Please like</p></body></html>","text":"Please like","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/874308923","repostId":1169973686,"repostType":4,"repost":{"id":"1169973686","pubTimestamp":1637725927,"share":"https://www.laohu8.com/m/news/1169973686?lang=&edition=full","pubTime":"2021-11-24 11:52","market":"sg","language":"en","title":"iX Biopharma hands Seelos exclusive rights for lead drug Wafermine","url":"https://stock-news.laohu8.com/highlight/detail?id=1169973686","media":"businesstimes","summary":"CATALIST-LISED iX Biopharma has inked an exclusive agreement to license its lead drug under developm","content":"<div>\n<p>CATALIST-LISED iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics - a clinical-stage biopharmaceutical company.\nSeelos, which ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/ix-biopharma-hands-seelos-exclusive-rights-for-lead-drug-wafermine\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iX Biopharma hands Seelos exclusive rights for lead drug Wafermine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niX Biopharma hands Seelos exclusive rights for lead drug Wafermine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 11:52 GMT+8 <a href=https://www.businesstimes.com.sg/companies-markets/ix-biopharma-hands-seelos-exclusive-rights-for-lead-drug-wafermine><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CATALIST-LISED iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics - a clinical-stage biopharmaceutical company.\nSeelos, which ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/ix-biopharma-hands-seelos-exclusive-rights-for-lead-drug-wafermine\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"42C.SI":"IX生物制药"},"source_url":"https://www.businesstimes.com.sg/companies-markets/ix-biopharma-hands-seelos-exclusive-rights-for-lead-drug-wafermine","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169973686","content_text":"CATALIST-LISED iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics - a clinical-stage biopharmaceutical company.\nSeelos, which develops novel therapeutics for central nervous systems disorders, will have exclusive worldwide rights for Wafermine, with the exception of China, including Hong Kong, Macau and Taiwan - which iX Biopharma will retain the rights for.\nSeelos will also have worldwide rights to products incorporating R- and S- enantiomers of ketamine being developed using iX Biopharma's WaferiX technology.\nAs part of the deal, iX Biopharma will receive a US$9 million upfront payment in cash and shares from Seelos. The speciality pharmaceutical company will also be eligible for up to US$239 million in development and sales milestone payments.\nMoreover, iX Biopharma will receive \"double-digit\" percentage royalties on future net sales of any products which incorporate the R- and S- enantiomers of ketamine using its WaferiX technology.\niX Biopharma chairman and chief executive Eddy Lee said Seelos' deep insights in ketamine drug development make them an ideal partner to further the development of Wafermine and other sublingual ketamine products.\n\"Licensing our WaferiX-based pharmaceutical drugs to suitable third parties for development and commercialisation is a core strategy to unlock the value of our assets,\" he added.\nKetamine provides a non-opioid approach for the treatment of pain by targeting the NMDA (N-methyl-D-aspartate) receptor. It also has the potential to treat depression, iX Biopharma said, citing clinical studies.\nThe company's lead product Wafermine provides ketamine in the form of easily-dissolved wafers for faster therapeutic action and predictable dosing, it added.\nShares of iX Biopharma were trading 1.9 per cent or S$0.005 lower at S$0.255 as at 11.05 am on Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":37,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":10,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/874308923"}
精彩评论